DCIS Understood

Donate

Demystifying

Ductal Carcinoma in Situ

"I want patients to understand their options and have choices."
- Ann H. Partridge, MD, MPH

"We need to tailor therapies better for individual patients….the problem is that we overtreat the many to benefit the few."
- Lawrence J. Solin, MD

"There is risk both with treatment and with treatment deescalation, and we need to be able to quantify that trade off in a much better way for an individual patient."
- Shelley Hwang, MD, MPH

"The next few years will witness the publication of major trial results and potentially chart a new course of DCIS management."
- Lars J. Grimm, MD, MHS

Helping patients understand DCIS and make informed treatment decisions.

What's New

June 11, 2026

“Baby TAM” After DCIS: What New Research Says About Menopausal Status and Your Risk

If you’ve been treated for ductal carcinoma in situ (DCIS) and had a conversation with your doctor about tamoxifen, you may have heard about a lower-dose option sometimes called “baby TAM.” New research presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2026 — and simultaneously published in the Journal of Clinical Oncology — sheds important light on how well this low-dose approach works, and why your menopausal status may matter more than previously understood.

Get the latest DCIS updates

Your donation goes directly to expanding the information on this website

Donate

DCIS Understood

The mission of DCIS Understood is to increase awareness and knowledge of Ductal Carcinoma in Situ (DCIS) and to accelerate research of DCIS through education, advocacy and funding.

DCIS Understood is a registered 501(c)(3) nonprofit organization.
EIN is 99-4323785

Stay Connected:

[email protected]
917-232-3329

Demystifying

Ductal Carcinoma in Situ